ArticleThe Annals of thoracic surgery2026
Evaluating Antegrade Cerebral Perfusion Flow Rates for Neuroprotection During Hypothermic Circulatory Arrest.
Article in The Annals of thoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundHypothermia is used to reduce metabolic demand and ischemic neurologic injury during cardiac surgery requiring circulatory arrest. However, adverse effects of hypothermia limit safe arrest times. Antegrade cerebral perfusion (ACP) may allow longer arrest; however, randomized data are lacking to inform optimal operative strategies. We hypothesized that an ideal ACP flow rate could be determined that would provide neurocognitive protection during hypothermic circulatory arrest (HCA).
methodsEighteen animals underwent HCA (90 minutes) and unilateral ACP through the carotid artery at 2.5, 5, or 10 mL/kg per minute. Animals were compared with controls that received intravenous ketamine (potentially neuroprotective) but no ACP. Animals were survived and assessed for 3 days. Outcomes included behavior deficit scores, cognition (novel object recognition), neuropathologic injury, inflammatory response, and neurologic injury biomarkers.
resultsNo differences in postoperative behavioral deficit scores, cognition, or neuropathologic injury were observed in animals receiving ACP at any rate. ACP animals demonstrated improved behavioral scores vs controls on postoperative days 1 and 2 (both P values < .05). Cognition was preserved in ACP-treated animals, with the 10 mL/kg per minute group demonstrating postoperative preference for the novel object (P < .05), consistent with intact cognition. Neuropathologic analysis demonstrated a trend toward lower global brain injury scores in ACP-treated animals compared with controls (P = .06). Neurologic injury biomarkers and inflammatory markers were attenuated with high-flow ACP relative to lower flow groups (P < .05).
conclusionsOur findings support the use of ACP as a neuroprotection strategy and suggest that increased flow rates within the studied range could be beneficial in patients undergoing HCA.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.